by Raymond Tel | Oct 21, 2024 | News
We are happy to share great news! SUL-238 is currently in Phase I clinical trials in collaboration with our Turkish partner GEN Ilac. It is the first drug reported that leads to persisting improvement of vascular aging. This work has recently been published in The...
by Raymond Tel | Sep 10, 2024 | News
We are excited to announce that our lead drug candidate SUL-238 has been featured in the prestigious journal Nature Medicine. The article highlights hibernation as a source of inspiration for drug development, which also forms the basis for our groundbreaking...
by Raymond Tel | May 23, 2024 | News
https://open.spotify.com/episode/7sC62GDjmc0g2oQFu4XZo0...
by Raymond Tel | May 17, 2024 | News
Wintersleep or hibernation is used by some animals to survive harsh environmental conditions, but not all animals can hibernate. Interestingly, hibernators possess protective mechanisms that allows them to withstand or repair cell and organ damage that develops during...
by Raymond Tel | Mar 28, 2024 | News
Sulfateq is happy to announce that a new scientific manuscript detailing the safety of SUL-138 is published in the leading journal Toxicology Reports. This manuscript details the safety, tolerability and toxicokinetic data of SUL-138, an obligatory step in drug...
by Raymond Tel | Feb 24, 2024 | News
This week, the first dosings of SUL-238 in healthy volunteers in a Phase I study marks a major milestone in the clinical development of this hibernation-derived, first-in-class drug. The phase I study investigates the safety, tolerability and pharmacokinetics after...
by Raymond Tel | Apr 7, 2023 | News
Great news! A new scientific paper has been published about the potential of a new medicine, SUL-138, to help treat sepsis. Sepsis is a serious health problem, but right now doctors can only use antibiotics and supportive care to help patients. SUL-138 targets the...
by Raymond Tel | Dec 14, 2022 | News
Alzheimer’s Disease (AD) is a complex and progressive neurodegenerative disease which is characterized by memory loss and cognitive impairment. It is one of the most prevalent neurodegenerative diseases and it is estimated that the number of patients will increase...
by Raymond Tel | Aug 1, 2022 | News
We at Sulfateq are very proud to have reached the finals out of more than twenty applications. The Innovation Award is awarded to the innovation with the most impact in the field of Life Sciences & Health. During the final on September 27, we will pitch our...
